hemoglobin, all non-invasively and continuously. The system is designed for use in hospitals including operating and recovery rooms and intensive care units as well as in outpatient sites and emergency services. OrSense's non-invasive hemoglobin/hematocrit monitor was granted the CE approval and was tested on over 4,000 patients and donors at 15 sites in the U.S. and Europe. The Company's products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches.